Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin Lymphoma

Video

Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.

Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.

Investigators are in the early stages of evaluating CD30-directed CAR T-cell therapies as well as ADCs, says Mei. In addition to brentuximab vedotin (Adcetris), which is an FDA-approved CD30-targeted ADC, investigators are looking at CD25-targeted ADCs, which have shown preliminary responses in heavily pretreated patients, adds Mei. However, this is not an exhaustive list as there are several ongoing trials looking at additional immunotherapies.

The CD25-targeted ADC is currently in ongoing trials. CD25 is a promising target because it is commonly expressed on the surface of malignant lymphoma cells, explains Mei. Preliminary data have shown significant responses with this agent as well as a moderate toxicity profile. As such, it may be a potentially viable option for patients with refractory disease who have exhausted all other therapies, concludes Mei.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.